Source: Sharecast
Under the agreement, GSK will receive an upfront payment of $300m, followed by a further $100m on US Food And Drug Administration approval, which was expected to be received before the transaction closes.
GSK will also be eligible for a further $20m tied to EU and UK approvals and up to $270m in sales‑based milestones, alongside tiered double‑digit royalties on global net sales.
Linerixibat holds Orphan Drug Designation in the US, EU and Japan, and priority review status in China. Marketing applications were already under review across the US, EU, UK, China and Canada, supported by positive phase III GLISTEN data showing rapid and sustained improvements in cholestatic pruritus and itch‑related sleep disruption versus placebo. However, the drug has yet to be approved in any market.
As of 0840 GMT, GSK shares were down 1.62% at 2,005p.
Reporting by Iain Gilbert at Sharecast.com